To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023:That is the question

Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis

Webers, C.
Ortolan, A.
Sepriano, A.
Falzon, L.
Baraliakos, X.
Landewe, R.B.M.
Ramiro, S.
Heijde, D. van der
Nikiphorou, E.

October 2022

Objective To update the evidence on efficacy and safety of biological disease-modifying antirheumati...

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Ramiro, S.
Nikiphorou, E.
Sepriano, A.
Ortolan, A.
Webers, C.
Baraliakos, X.
Landewe, R.B.M.
Bosch, F.E. van den
Boteva, B.
Bremander, A.
Carron, P.
Ciurea, A.
Gaalen, F.A. van
Geher, P.
Gensler, L.
Hermann, J.
Hooge, M. de
Husakova, M.
Kiltz, U.
Lopez-Medina, C.
Machado, P.M.
Marzo-Ortega, H.
Molto, A.
Navarro-Compan, V.
Nissen, M.J.
Pimentel-Santos, F.M.
Poddubnyy, D.
Proft, F.
Rudwaleit, M.
Telkman, M.
Zhao, S.S.
Ziade, N.
Heijde, D. van der

October 2022

Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommen...

New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice

Dubash, S
McGonagle, D
Marzo-Ortega, H

March 2018

Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that encompasses ankylosing spon...

To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023:That is the question

Lukasik, Zuzanna
Carron, Philippe
Webers, Casper

August 2023

The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to...

Tapering or discontinuation of biological disease-modifying antirheumatic drugs in axial spondyloarthritis:A review of the literature and discussion on current practice

Webers, Casper
Nikiphorou, Elena
Boonen, Annelies
Ramiro, Sofia

January 2023

Biological disease-modifying antirheumatic drugs (bDMARDs) have taken up an important role in the ma...

Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis

Vinson, D.
Molet-Benhamou, L.
Degboe, Y.
Broeder, A. den
Ibrahim, F.
Pontes, C.
Westhovens, R.
Zavada, J.
Pham, T.
Barnetche, T.
Constantin, A.
Ruyssen-Witrand, A.

January 2020

OBJECTIVES: To systematically review the impact of tapering targeted therapies (bDMARDs or JAKis) on...

Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis

Uhrenholt, L
Christensen, R
Dinesen, WKH
Liboriussen, CH
Andersen, SS
Dreyer, L
Schlemmer, A
Hauge, E-M
Skrubbeltrang, C
Taylor, PC
Kristensen, S

January 2021

Objective To evaluate flare risk when tapering or withdrawing biologic or targeted synthetic DMARDs ...

Axial Spondyloarthritis in the Era of Precision Medicine

van Bentum, Rianne E.
van der Horst-Bruinsma, Irene E.

May 2020

In axial spondyloarthritis (axSpA), the first treatment step is generally a nonsteroidal anti-inflam...

Disease activity guided stepwise tapering or discontinuation of rhTNFR:Fc, an etanercept biosimilar, in patients with ankylosing spondylitis: a prospective, randomized, open-label, multicentric study

Ting Zhang
Jianing Zhu
Dongyi He
Xiaowei Chen
Hongzhi Wang
Ying Zhang
Qin Xue
Weili Liu
Guangbo Xiang
Yasong Li
Zhongming Yu
Huaxiang Wu

May 2020

Background: The aim of this study was to evaluate disease-activity-guided stepwise tapering or disco...

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Ortolan, A.
Webers, C.
Sepriano, A.
Falzon, L.
Baraliakos, X.
Landewe, R.B.M.
Ramiro, S.
Heijde, D. van der
Nikiphorou, E.

October 2022

Objective To update the evidence of non-biological treatments for axial spondyloarthritis (axSpA), a...

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

Landewe, R.B.M.
Heijde, D. van der
Dougados, M.
Baraliakos, X.
Bosch, F.E. van den
Gaffney, K.
Bauer, L.
Hoepken, B.
Davies, O.R.
Peyrecave, N. de
Thomas, K.
Gensler, L.

July 2020

Background The best strategy for maintaining clinical remission in patients with axial spondyloarthr...

Recent advances in managing axial spondyloarthritis

Agrawal, P
Machado, PM

January 2020

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that predominantly affec...

What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?

Atzeni, Fabiola
Benucci, Maurizio
Talotta, Rossella
Masala, Ignazio Francesco
Sarzi-Puttini, Piercarlo
Govoni, Marcello

January 2016

Introduction: Treatment with biological DMARDs (bDMARDs) has meant that remission or low disease act...

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.

Ramiro, Sofia
Nikiphorou, Elena
Sepriano, Alexandre
Ortolan, Augusta
Webers, Casper
Baraliakos, Xenofon
Landewé, Robert B M
Van den Bosch, Filip E
Boteva, Boryana
Bremander, Ann
Carron, Philippe
Ciurea, Adrian
van Gaalen, Floris A
Géher, Pál
Gensler, Lianne
Hermann, Josef
de Hooge, Manouk
Husakova, Marketa
Kiltz, Uta
López-Medina, Clementina
Machado, Pedro M
Marzo-Ortega, Helena
Molto, Anna
Navarro-Compán, Victoria
Nissen, Michael J
Pimentel-Santos, Fernando M
Poddubnyy, Denis
Proft, Fabian
Rudwaleit, Martin
Telkman, Mark
Zhao, Sizheng Steven
Ziade, Nelly
van der Heijde, Désirée

October 2022

To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommendations for...

Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: A systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Regel, A.
Sepriano, A.
Baraliakos, X.
Van Der Heijde, D.
Braun, J.
Landewé, R.
Van Den Bosch, F.
Falzon, L.
Ramiro, S.

January 2017

To assess the efficacy and safety of non-biological therapies in patients with axial spondyloarthrit...

Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis

Webers, C.
Ortolan, A.
Sepriano, A.
Falzon, L.
Baraliakos, X.
Landewe, R.B.M.
Ramiro, S.
Heijde, D. van der
Nikiphorou, E.

October 2022

Objective To update the evidence on efficacy and safety of biological disease-modifying antirheumati...

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Ramiro, S.
Nikiphorou, E.
Sepriano, A.
Ortolan, A.
Webers, C.
Baraliakos, X.
Landewe, R.B.M.
Bosch, F.E. van den
Boteva, B.
Bremander, A.
Carron, P.
Ciurea, A.
Gaalen, F.A. van
Geher, P.
Gensler, L.
Hermann, J.
Hooge, M. de
Husakova, M.
Kiltz, U.
Lopez-Medina, C.
Machado, P.M.
Marzo-Ortega, H.
Molto, A.
Navarro-Compan, V.
Nissen, M.J.
Pimentel-Santos, F.M.
Poddubnyy, D.
Proft, F.
Rudwaleit, M.
Telkman, M.
Zhao, S.S.
Ziade, N.
Heijde, D. van der

October 2022

Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommen...

New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice

Dubash, S
McGonagle, D
Marzo-Ortega, H

March 2018

Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that encompasses ankylosing spon...

To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023:That is the question

Lukasik, Zuzanna
Carron, Philippe
Webers, Casper

August 2023

The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to...

Tapering or discontinuation of biological disease-modifying antirheumatic drugs in axial spondyloarthritis:A review of the literature and discussion on current practice

Webers, Casper
Nikiphorou, Elena
Boonen, Annelies
Ramiro, Sofia

January 2023

Biological disease-modifying antirheumatic drugs (bDMARDs) have taken up an important role in the ma...

Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis

Vinson, D.
Molet-Benhamou, L.
Degboe, Y.
Broeder, A. den
Ibrahim, F.
Pontes, C.
Westhovens, R.
Zavada, J.
Pham, T.
Barnetche, T.
Constantin, A.
Ruyssen-Witrand, A.

January 2020

OBJECTIVES: To systematically review the impact of tapering targeted therapies (bDMARDs or JAKis) on...

Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis

Uhrenholt, L
Christensen, R
Dinesen, WKH
Liboriussen, CH
Andersen, SS
Dreyer, L
Schlemmer, A
Hauge, E-M
Skrubbeltrang, C
Taylor, PC
Kristensen, S

January 2021

Objective To evaluate flare risk when tapering or withdrawing biologic or targeted synthetic DMARDs ...

Axial Spondyloarthritis in the Era of Precision Medicine

van Bentum, Rianne E.
van der Horst-Bruinsma, Irene E.

May 2020

In axial spondyloarthritis (axSpA), the first treatment step is generally a nonsteroidal anti-inflam...

Disease activity guided stepwise tapering or discontinuation of rhTNFR:Fc, an etanercept biosimilar, in patients with ankylosing spondylitis: a prospective, randomized, open-label, multicentric study

Ting Zhang
Jianing Zhu
Dongyi He
Xiaowei Chen
Hongzhi Wang
Ying Zhang
Qin Xue
Weili Liu
Guangbo Xiang
Yasong Li
Zhongming Yu
Huaxiang Wu

May 2020

Background: The aim of this study was to evaluate disease-activity-guided stepwise tapering or disco...

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Ortolan, A.
Webers, C.
Sepriano, A.
Falzon, L.
Baraliakos, X.
Landewe, R.B.M.
Ramiro, S.
Heijde, D. van der
Nikiphorou, E.

October 2022

Objective To update the evidence of non-biological treatments for axial spondyloarthritis (axSpA), a...

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

Landewe, R.B.M.
Heijde, D. van der
Dougados, M.
Baraliakos, X.
Bosch, F.E. van den
Gaffney, K.
Bauer, L.
Hoepken, B.
Davies, O.R.
Peyrecave, N. de
Thomas, K.
Gensler, L.

July 2020

Background The best strategy for maintaining clinical remission in patients with axial spondyloarthr...

Recent advances in managing axial spondyloarthritis

Agrawal, P
Machado, PM

January 2020

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that predominantly affec...

What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?

Atzeni, Fabiola
Benucci, Maurizio
Talotta, Rossella
Masala, Ignazio Francesco
Sarzi-Puttini, Piercarlo
Govoni, Marcello

January 2016

Introduction: Treatment with biological DMARDs (bDMARDs) has meant that remission or low disease act...

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.

Ramiro, Sofia
Nikiphorou, Elena
Sepriano, Alexandre
Ortolan, Augusta
Webers, Casper
Baraliakos, Xenofon
Landewé, Robert B M
Van den Bosch, Filip E
Boteva, Boryana
Bremander, Ann
Carron, Philippe
Ciurea, Adrian
van Gaalen, Floris A
Géher, Pál
Gensler, Lianne
Hermann, Josef
de Hooge, Manouk
Husakova, Marketa
Kiltz, Uta
López-Medina, Clementina
Machado, Pedro M
Marzo-Ortega, Helena
Molto, Anna
Navarro-Compán, Victoria
Nissen, Michael J
Pimentel-Santos, Fernando M
Poddubnyy, Denis
Proft, Fabian
Rudwaleit, Martin
Telkman, Mark
Zhao, Sizheng Steven
Ziade, Nelly
van der Heijde, Désirée

October 2022

To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommendations for...

Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: A systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Regel, A.
Sepriano, A.
Baraliakos, X.
Van Der Heijde, D.
Braun, J.
Landewé, R.
Van Den Bosch, F.
Falzon, L.
Ramiro, S.

January 2017

To assess the efficacy and safety of non-biological therapies in patients with axial spondyloarthrit...

Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis

Webers, C.
Ortolan, A.
Sepriano, A.
Falzon, L.
Baraliakos, X.
Landewe, R.B.M.
Ramiro, S.
Heijde, D. van der
Nikiphorou, E.

October 2022

Objective To update the evidence on efficacy and safety of biological disease-modifying antirheumati...

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Ramiro, S.
Nikiphorou, E.
Sepriano, A.
Ortolan, A.
Webers, C.
Baraliakos, X.
Landewe, R.B.M.
Bosch, F.E. van den
Boteva, B.
Bremander, A.
Carron, P.
Ciurea, A.
Gaalen, F.A. van
Geher, P.
Gensler, L.
Hermann, J.
Hooge, M. de
Husakova, M.
Kiltz, U.
Lopez-Medina, C.
Machado, P.M.
Marzo-Ortega, H.
Molto, A.
Navarro-Compan, V.
Nissen, M.J.
Pimentel-Santos, F.M.
Poddubnyy, D.
Proft, F.
Rudwaleit, M.
Telkman, M.
Zhao, S.S.
Ziade, N.
Heijde, D. van der

October 2022

Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommen...

New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice

Dubash, S
McGonagle, D
Marzo-Ortega, H

March 2018

Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that encompasses ankylosing spon...

To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023:That is the question

Abstract

Extracted data

To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023:That is the question

Abstract

Extracted data

Related items

Related items